Related references
Note: Only part of the references are listed.Factors affecting therapeutic compliance: A review from the patient’s perspective
Shu-Chuen Li
Therapeutics and Clinical Risk Management (2016)
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk
Anushka Patel et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2015)
Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes
Sieta T. de Vries et al.
JOURNAL OF PSYCHOSOMATIC RESEARCH (2014)
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care
Vanessa Selak et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease
Melvin Lafeber et al.
AMERICAN HEART JOURNAL (2013)
Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVD The UMPIRE Randomized Clinical Trial
Simon Thom et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
Prevalence of cardiovascular disease risk amongst the population eligible for the NHS Health Check Programme
Andrew R. H. Dalton et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2013)
Sync and Swim: The Impact of Medication Consolidation on Adherence in Medicaid Patients
Alexander Ross et al.
JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH (2013)
Cost-effectiveness of optimizing prevention in patients with coronary heart disease: the EUROASPIRE III health economics project
Delphine De Smedt et al.
EUROPEAN HEART JOURNAL (2012)
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Joep Perk et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2012)
Incidence and 30-day case fatality for acute myocardial infarction in England in 2010: national-linked database study
Kate Smolina et al.
EUROPEAN JOURNAL OF PUBLIC HEALTH (2012)
ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK
Kornelia Kotseva et al.
HEART (2012)
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
R. Ara et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2012)
The cardiovascular polypill in high-risk patients
Melvin Lafeber et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2012)
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Joep Perk et al.
EUROPEAN HEART JOURNAL (2012)
Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects
Paul Muntner et al.
AMERICAN HEART JOURNAL (2011)
Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach
Uwe Zeymer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Obesity 2 Health and economic burden of the projected obesity trends in the USA and the UK
Y. Claire Wang et al.
LANCET (2011)
Increased risk of stroke after discontinuation of acetylsalicylic acid: A UK primary care study
L. A. Garcia Rodriguez et al.
NEUROLOGY (2011)
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
Kornelia Kotseva et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2009)
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
LANCET (2009)
Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population
Gines Sanz et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2009)
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study
Douglas C. A. Taylor et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2009)
Adherence to statin or aspirin or both in patients with established cardiovascular disease:: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome
Li Wei et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction medicare beneficiaries
Niteesh K. Choudhry et al.
CIRCULATION (2008)
Trends in secondary prevention of ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment
S. DeWilde et al.
HEART (2008)
Estimated 10-year cardiovascular risk in a British population: results of a national screening project
H. A. W. Neil et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study
Sheena E. Ramsay et al.
JOURNAL OF PUBLIC HEALTH (2007)
Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: A pooled meta-analysis of randomized placebo-controlled trials
Sandeep A. Saha et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2007)
A systematic review and economic evaluation of statins for the prevention of coronary events
S. Ward et al.
HEALTH TECHNOLOGY ASSESSMENT (2007)
Oral antiplatelet therapy in secondary prevention of cardiovascular events - An assessment from the payer's perspective
Bart Heeg et al.
PHARMACOECONOMICS (2007)
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis
Thomas A. Gaziano et al.
LANCET (2006)
Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease
LK Newby et al.
CIRCULATION (2006)
A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention
PA Scuffham et al.
CLINICAL THERAPEUTICS (2005)
Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin?
G Cotter et al.
AMERICAN HEART JOURNAL (2004)
An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK
PA Scuffham et al.
PHARMACOECONOMICS (2004)
A strategy to reduce cardiovascular disease by more than 80%
NJ Wald et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
